N.J.-based Hackensack University Medical Center became the second hospital in the world to implant the Impella Bridge-to-Recovery heart pump, New Jersey Business Magazine reported Aug. 18.
Cardiac surgeon Yuriy Dudiy, MD, implanted the device in a 63-year-old male diagnosed with advanced heart failure on July 18.
Impella BTR received FDA investigational device exemption in December 2021. It is a percutaneous forward-flow heart pump capable of greater than 6 liters of blood flow per minute. Less invasive than current left ventricular assist devices, it can be implanted through a small incision in the chest.
The device, developed by medical technology company Abiomed, is designed to provide patients with chronic heart failure a longer-term, minimally invasive heart pump option.
Hackensack medical center is one of five hospitals in the U.S. selected to participate in the FDA-approved clinical trial.